ArticleCell communication and signaling : CCS2026
Simulated microgravity models sex differences in knee osteoarthritis through a CD36-regulated mechano-metabolic circuit.
Article in Cell communication and signaling : CCS, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundSex differences in knee osteoarthritis (KOA) are well documented, but the molecular drivers within meniscal tissue remain unclear. We studied whether simulated microgravity (SMG) models sex‑dependent meniscal degeneration and whether the lipid scavenger receptor CD36 mediates these effects.
methodsHuman menisci from total knee arthroplasty (TKA) donors were analyzed (histology n = 5 females/5 males; flow cytometry and RT‑qPCR n = 7 females/7 males). In mice, we assessed spontaneous anterior‑horn mineralization by micro‑CT at 4, 12, and 24 weeks in wild‑type (WT) and CD36‑deficient (Cd36−/−) animals. Four‑week menisci were then encapsulated in 1% agarose and cultured for 3 weeks under static or SMG conditions with serial micro‑CT (days 0, 7, 14, 21), histology, bulk RNA‑seq, and DIA shotgun proteomics.
resultsFemale TKA menisci showed near‑complete glycosaminoglycan loss, disorganized type I collagen, and elevated hypertrophic markers (COL10A1, BMP2, IHH), with a trend toward more CD36 + cells. In vivo, a significant sex and genotype interaction emerged at 12 weeks in mouse model: Cd36−/− females displayed ~ 15% less mineralization than WT. Ex vivo, SMG increased mineralization in WT females by ~ 25% at day 7 and ~ 30% at day 21 compared to static, but had minimal effect in males; Cd36−/− females exhibited ~ 20–30% lower SMG‑induced mineralization than WT and preserved Safranin‑O and type II collagen. Transcriptomics under SMG revealed strong sex divergence: females showed enrichment of cell–matrix/mechanosignaling pathways, including ECM–receptor/focal‑adhesion and Ca/PI3K‑linked signaling, whereas males showed immune/osteoclast signatures. Proteomics paralleled these patterns: WT females under SMG had marked decreases in Col2a1, Col11a1, and Acan with increased oxidative‑phosphorylation proteins; Cd36−/− females showed reduced abundance of mitochondrial respiratory proteins and vesicle/mineralization‑associated factors, consistent with reduced mineralization and preserved ECM.
conclusionsSMG provides a controllable platform that recapitulates sex‑dependent, KOA‑like tissue degeneration. The data support a CD36-dependent mechanometabolic axis in females in which mechanical unloading disrupts ECM integrity, activates CD36-linked lipid handling with Ca/PI3K/AMPK signaling, and drives higher mitochondrial respiration and oxidative stress, culminating in ECM breakdown and mineralization, positioning CD36 as a promising sex-stratified therapeutic target in KOA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.